Folia Biologica
Journal of Cellular and Molecular Biology, Charles University 

Crossref logo

Fol. Biol. 2003, 49, 183-190

https://doi.org/10.14712/fb2003049050183

Efficacy and Safety of Inhaled Recombinant Interleukin-2 in High-Risk Renal Cell Cancer Patients Compared with Systemic Interleukin-2: an Outcome Study

Edith Huland1, A. Burger2, J. Fleischer3, P. Fornara4, E. Hatzmann5, A. Heidenreich6, H. Heinzer1, H. Heynemann4, L. Hoffmann7, R. Hofmann6, H. Huland1, I. Kämpfer7, M. Kindler2, H. Kirchner8, G. Mehlhorn9, T. H. Moniak9, U. Rebmann9, J. Roigas10, T. H. Schneider4, D. Schnorr10, H.-J. Schmitz3, R. Wenisch3, Z. Varga6, J. Vinke5

1Department of Urology, University Hospital Hamburg-Eppendorf, Germany
2Onkologische Schwerpunktpraxis, Berlin, Germany
3St. Carolus Krankenhaus, Görlitz, Germany
4Martin-Luther-Universität Halle-Wittenberg, Halle, Germany
5Chiron BV, Amsterdam
6Philipps-Universität Marburg, Marburg, Germany
7Waldklinikum GmbH, Gera, Germany
8Klinikum Siloah, Germany
9Diakonissenkrankenhaus, Dessau, Germany
10Department of Urology, Charite, Humboldt Universität Berlin, Germany

Received October 2003
Accepted October 2003

References

1. Atzpodien, J., Korfer, A., Franks, C. R., Poliwoda, H., Kirchner, H. (1990) Home therapy with recombinant interleukin-2 and interferon-alpha 2b in advanced human malignancies. Lancet 335, 1509-1512. <https://doi.org/10.1016/0140-6736(90)93039-R>
2. Atzpodien, J., Kirchner, H., deMulder, P., Bodenstein, H., Oliver, T., Palmer, P. A., Franks, C. R., Poliwoda, H. (1993) Subcutaneous recombinant interleukin-2 and α-interferon in patients with advanced renal cell carcinoma: results of a multicenter phase II study. Cancer Biother. 8, 289-300. <https://doi.org/10.1089/cbr.1993.8.289>
3. Atzpodien, J., Lopez Hänninen, E., Kirchner, H., Bodenstein, H., Pfreundschuh, M., Rebmann, U., Metzner, B., Illiger, H. J., Jakse, G., Niesel, T., Scholtz, H.-J., Wilhelm, S. (1995) Multiinstitutional home-therapy trial of recombinant interleukin-2 and interferon alfa-2 in progressive metastatic renal cell carcinoma. J. Clin. Oncol. 13, 497-501. <https://doi.org/10.1200/JCO.1995.13.2.497>
4. Bukowski, R. M. (1997) Natural history and therapy of metastatic renal cell carcinoma: the role of interleukin-2. Cancer 80, 1198-1220. <https://doi.org/10.1002/(SICI)1097-0142(19971001)80:7<1198::AID-CNCR3>3.0.CO;2-H>
5. Buzio, C., Palma, G. de., Passalacqua, R., Potenzoni, D., Ferrozzi, F., Cattabiani, M. A., Manenti, L., Borghetti, A. (1997) Effectiveness of very low doses of immunotherapy in advanced renal cell cancer. Br. J. Cancer 76, 541-544. <https://doi.org/10.1038/bjc.1997.422>
6. Cheever, M. A., Greenberg, P. D., Fefer, A., Gillis, S. (1982) Augmentation of the anti-tumour therapeutic efficacy of long-term cultured T lymphocytes by in vivo administration of purified interleukin-2. J. Exp. Med. 155, 968-980. <https://doi.org/10.1084/jem.155.4.968>
7. Clark, J. I., Gaynor, E., Martone, B. (1999) Daily subcutaneous ultra-low-dose interleukin 2 with daily low-dose interferon-alpha in patients with advanced renal cell carcinoma. Clin. Cancer Res. 5, 2374-2380.
8. Debatin, K. M., Woodroofe, C., Lahm, H., Fischer, J., Falk, W. (1989) Lack of interleukin-2 (IL-2) dependent growth of TAC positive T-ALL/NHL cells is due to the expression of only low affinity receptors of IL-2. Leukemia 8, 566-571.
9. deKernion, J. B., Sarna, G., Figlin, R., Lindner, A., Smith, R. B. (1983) The treatment of renal cell carcinoma with human leukocyte alpha-interferon. J. Urol. 130, 1063-1066. <https://doi.org/10.1016/S0022-5347(17)51686-9>
10. Elson, P. J., Witte, R. S., Trump, D. L. (1988) Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma. Cancer Res. 48, 7310-7313.
11. Figlin, R., Gitlitz, B., Franklin, J., Dorey, F., Moldawer, N., Rausch, J., Kernion, J. de., Belldegrun, A. (1997) Interleukin 2-based immunotherapy for the treatment of metastatic renal cell carcinoma: an analysis of 203 consecutively treated patients. Cancer J. Sci. Am. 3, S92-S97.
12. Foa, R., Guarini, A., Gansbacher, B. (1992) IL-2 treatment for cancer: from biology to gene therapy. Br. J. Cancer 6, 992-998. <https://doi.org/10.1038/bjc.1992.400>
13. Fossa, S. D., Kramar, A., Droz, J. P. (1994) Prognostic factors and survival in patients with metastatic renal cell carcinoma treated with chemotherapy or interferon-alpha. Eur. J. Cancer 30A, 1310-1314. <https://doi.org/10.1016/0959-8049(94)90179-1>
14. Goepel, M., Rubben, H. (1991) Adjuvant therapy in renal cancer. World J. Urol. 9, 232-236. <https://doi.org/10.1007/BF00182847>
15. Grootendorst, P. V., Feeny, D. H., Furlong, W. (1997) Does it matter whom and how you ask? Interand intra-rater agreement in the Ontario Health Survey. J. Clin. Epidemiol. 50, 127-135. <https://doi.org/10.1016/S0895-4356(96)00314-9>
16. Heidenreich, A., Neubauer, S. (1999) Interleukin-2 inhalation therapy in pulmonary metastases of renal cell cancer - Cologne experience. Anticancer Res. 19, 2003-2004.
17. Heinzer, H., Mir, T. S., Huland, E., Huland, H. (1999) Subjective and objective prospective, long-term analysis of quality of life during inhaled interleukin-2 immunotherapy. J. Clin. Oncol. 17, 3612-3620. <https://doi.org/10.1200/JCO.1999.17.11.3612>
18. Huland, E. (2001) Interleukin-2 and cancer - physiological and pharmacological uses. Folia Biol. (Praha) 47, 111-112.
19. Huland, E., Huland, H., Heinzer, H. (1992) Interleukin-2 by inhalation: local therapy for metastatic renal cell carcinoma. J. Urol. 147, 344-348. <https://doi.org/10.1016/S0022-5347(17)37233-6>
20. Huland, E., Heinzer, H., Mir, T. S., Huland, H.(1997) Inhaled interleukin-2 therapy in pulmonary metastatic renal cell carcinoma: six years of experience. Cancer J. Sci. Am. 3, S98-S105.
21. Huland, E., Heinzer, H., Huland, H. (1999) Treatment of pulmonary metastatic renal-cell carcinoma in 116 patients using inhaled interleukin-2 (IL-2). Anticancer Res. 19, 2679-2683.
22. Huland, E., Heinzer, H., Huland, H. (2000a) A comparison of systemic versus inhaled recombinant IL-2 administration for the treatment of metastatic renal cell carcinoma. Folia Biol. (Praha) 46, 241-250.
23. Huland, E., Heinzer, H., Huland, H., Yung, R. (2000b) Overview of interleukin-2 inhalation therapy. Cancer J. Sci. Am. 6, S104-S112.
24. Huland, E., Heinzer, H., Timm, S., Aalamian, M., Huland, H. (2002) Immunotherapy for metastatic renal-cell carcinoma in Germany: a nationwide survey. Urologe A 41, 282-287. <https://doi.org/10.1007/s00120-001-0170-2>
25. Jones, M., Philip, T., Palmer, P., von der Maase, H., Vinke, J., Elson, P., Franks, C. R., Selby, P. (1993) The impact of interleukin-2 on survival in renal cancer: a multivariate analysis. Cancer Biother. 4, 275-288. <https://doi.org/10.1089/cbr.1993.8.275>
26. Kolitz, J. E., Mertelsmann, R. (1991) The immunotherapy of human cancer with interleukin-2: present status and future directions. Cancer Invest. 9, 529-542. <https://doi.org/10.3109/07357909109018951>
27. Lee, R. E., Lotze, M. T., Skibber, J. M. (1989) Cardiorespiratory effects of immunotherapy with interleukin-2. J. Clin. Oncol. 7, 7-20. <https://doi.org/10.1200/JCO.1989.7.1.7>
28. Lorenz, J., Wilhelm, K., Kessler, M. (1996) Phase I trial of inhaled natural interleukin 2 for treatment of pulmonary malignancy: toxicity, pharmacokinetics, and biological effects. Clin. Cancer Res. 2, 1115-1122.
29. Motzer, R. J., Mazumdar, M., Bacik, J. (2000) Effect of cytokine therapy on survival for patients with advanced renal cell carcinoma. J. Clin. Oncol. 18, 1928-1935. <https://doi.org/10.1200/JCO.2000.18.9.1928>
30. Motzer, R. J., Mazumdar, M., Bacik, J., Berg, W., Amsterdam, A., Ferrara, J. (1999) Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J. Clin. Oncol. 17, 2530-2540. <https://doi.org/10.1200/JCO.1999.17.8.2530>
31. Nakamoto, T., Kasaoka, Y., Mitani, S., Usui, T. (1997) Inhalation of interleukin-2 combined with subcutaneous administration of interferon for the treatment of pulmonary metastases from renal cell carcinoma. Int. J. Urol. 4, 343-348. <https://doi.org/10.1111/j.1442-2042.1997.tb00205.x>
32. Négrier, S., Philip, T., Stoter, G., Fossa, S. D., Janssen, S., Iacone, A., Cleton, F. S., Eremin, O., Israel, L., Jasmin, C., Rugarli, C., von der Maasse, H. (1989) Interleukin-2 with or without LAK cells in metastatic renal cell carcinoma: a report of a European multicentre study. Eur. J. Cancer Clin. Oncol. 25, S21-S28.
33. Oldham, R. K. (1984) Biological response modifiers program workshop, îIn vivo-effects of IL-2î. J. Biol. Response Modif. 3, 455-532.
34. Palmer, P. A., Vinke, J., Philip, T., Negrier, S., Atzpodien, J., Kirchner, H., Oskam, R., Franks, C. R. (1992) Prognostic factors for survival in patients with advanced renal cell carcinoma treated with recombinant interleukin-2. Ann. Oncol. 3, 475-480. <https://doi.org/10.1093/oxfordjournals.annonc.a058239>
35. Palmer, P. A., Atzpodien, J., Philip, T., Negrier, S., Kirchner, H., von der Maase, H., Geertsen, P., Evers, P., Loriaux, E., Oskam, R., Roest, G., Vinke, J., Franks, C. R. (1993) A comparison of 2 modes of administration of recombinant interleukin-2: continuous intravenous infusion alone versus subcutaneous administration plus interferon alpha in patients with advanced renal cell carcinoma. Cancer Biother. 8, 123-136. <https://doi.org/10.1089/cbr.1993.8.123>
36. Patel, N. P., Lavengood, R. W. (1977) Renal cell cancer: natural history and results of treatment. J. Urol. 119, 722-726. <https://doi.org/10.1016/S0022-5347(17)57611-9>
37. Piltz, S., Meimarakis, G., Wichmann, M., Hatz, R., Schildberg, F., Fuerst, H. (2002) Long-term results after pulmonary resection of renal cell carcinoma metastases. Ann. Thorac. Surg. 73, 1082-1087. <https://doi.org/10.1016/S0003-4975(01)03602-5>
38. Pizza, G., De Vinci, C., Lo, C. G. (2001) Immunotherapy of metastatic kidney cancer. Int. J. Cancer 94, 109-120. <https://doi.org/10.1002/ijc.1426>
39. Ravaud, A., Négrier, S., Cany, L., Merrouche, Y., Guillou, M. Le., Blay, J. Y., Clavel, M., Gaston, R., Oskam, R., Philip, T. (1994) Subcutaneous low-dose recombinant interleukin 2 and alpha-interferon in patients with metastatic renal cell carcinoma. Br. J. Cancer 69, 1111-1114. <https://doi.org/10.1038/bjc.1994.218>
40. Roigas, J. (1999) Inhalation of interleukin-2 as second-line treatment: CharitÈ experience. Anticancer Res. 19, 2010-2011.
41. Rosenberg, S. A., Lotze, M. T., Muul, L. M., Leitman, S., Chang, A. E. (1985) Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with cancer. N. Eng. J. Med. 313, 1485-1492. <https://doi.org/10.1056/NEJM198512053132327>
42. Rosenberg, S. A., Lotze, M. T., Yang, J. C., Abersold, P. M., Lineham, W. M, (1989) Experience with the use of highdose interleukin-2 in the treatment of 652 cancer patients. Ann. Surg. 210, 474-485. <https://doi.org/10.1097/00000658-198910000-00008>
43. Rosenberg, S. A., Yang, J. C., Topalian, S. L. (1994) Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA 271, 907-913. <https://doi.org/10.1001/jama.1994.03510360033032>
44. Sosman, J. A., Kohler, P. C., Hank, J. A. (1988) Repetitive weekly cycles of interleukin-2. II. Clinical and immunologic effects of dose, schedule, and addition of indomethacin. J. Natl. Cancer Inst. 80, 1451-1461. <https://doi.org/10.1093/jnci/80.18.1451>
45. Stahl, M., Wilke, H.-J., Seeber S., Schmoll, H.-J. (1992) Cytokines and cytotoxic agents in renal cell carcinoma: a review. Semin. Oncol. 19, S70-S79.
46. West, W. H., Tauerm, K. W., Yanellim, J. R., Marshall, G. D., Orr, D.W., Thurman, G. B., Oldham, R. K. (1987) Constant infusion of recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N. Eng. J. Med. 316, 898-905. <https://doi.org/10.1056/NEJM198704093161502>
47. Zissel, G., Aulitzky, W. E., Lorenz, J., Huber, C., MullerQuernheim, J. (1996) Induction of accessory cell function of human alveolar macrophages by inhalation of human natural interleukin-2. Cancer Immunol. Immunother. 42, 122-126. <https://doi.org/10.1007/s002620050261>
front cover

ISSN 0015-5500 (Print) ISSN 2533-7602 (Online)

Open access journal

Submissions

Archive